Results 301 to 310 of about 34,959 (356)

The Real-World Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C in Patients Active Malignancies. [PDF]

Cancers (Basel)
Dąbrowska M, Jaroszewicz J, Sitko M, Janocha-Litwin J, Zarębska-Michaluk D, Janczewska E, Lorenc B, Tudrujek-Zdunek M, Parfieniuk-Kowerda A, Klapaczyński J, Berak H, Socha Ł, Dobracka B, Dybowska D, Mazur W, Ważny Ł, Flisiak R.   +16 more
europepmc   +1 more source

Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis. [PDF]

Pharmacoeconomics
Martin MT, Rajagopalan K, Makhija D, Turkistani F, Burk C, Rock M, Hsiao A, Reau N.   +7 more
europepmc   +1 more source

High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam. [PDF]

Pharmacol Res Perspect
Vo TD, Bui VTT, Lam HT, Bui QTH.
europepmc   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C-A Systematic Review and Meta-Analysis. [PDF]

Diseases
Hamran S, Al-Rajhi AA, Jasim K, Al-Theyab MA, Elahtam M, Al-Hail MK, Al-Fahaidi W, Khamis YA, Dweidri Y, Elzouki AN, Chivese T.   +10 more
europepmc   +1 more source

Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals. [PDF]

Microorganisms
Tani J, Masaki T, Oura K, Tadokoro T, Morishita A, Kobara H.   +5 more
europepmc   +1 more source

Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Direct-acting antivirals for paediatric HCV: we got there

Nature Reviews Gastroenterology & Hepatology, 2017
In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.
Etienne M Sokal
openaire   +4 more sources

Antiviral resistance and direct-acting antiviral agents for HCV

Antiviral Therapy, 2012
Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development. DAA treatment of HCV infection, however, leads to the selection of viral variants (produced by the error-prone HCV polymerase) that are resistant to the DAA agent in use ...
Aloia, A., Locarnini, S., Beard, M.
openaire   +3 more sources

Direct-acting antiviral retreatment patterns for hepatitis C

Journal of Managed Care & Specialty Pharmacy, 2022
BACKGROUND: Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However, limited research exists to characterize rates of retreatment across different DAA agents or potential factors that may increase retreatment risk.
Shaquib Al, Hasan, Daniel G, Dauner, Abhijeet, Rajpurohit, Joel F, Farley   +3 more
openaire   +2 more sources